Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks To Open Cautiously Higher, Earnings In Focus

Wed, 23rd Jul 2014 11:49

LONDON (Alliance News) - US stocks are set to open cautiously higher Wednesday, boosted by the the lack of consensus among EU leaders to impose sector-wide sanctions on the Russian economy, but muted in trepidation of a raft of corporate earnings.

Currently, the DJIA, the S&P 500, and the Nasdaq Composite all look set to open about 0.1% higher.

Investors have had a mixed reaction to the big technology stock earnings released after the market close Tuesday. Apple shares are 0.5% lower in the pre-market despite beating earnings per share expectations as sales were slightly lighter than expected, while Microsoft shares are about 1.5% higher after it announced its own numbers.

The focus will remain on US earnings, particularly the biotechnology and social media stocks given Fed Chair Janet Yellen's recent comments that valuations in those particular sectors look "stretched." All eyes will be on Facebook the company reports after the US closing bell.

"While the Federal Reserve is perhaps not the best source of equity analysis the comments do highlight the importance of today’s earnings reports from Biogen, Gilead Sciences and Facebook in justifying overall stock market valuations," said CMC Markets market analyst Jasper Lawler.

Pepsico has done what its soft drink rival Coca-Cola failed to do on Tuesday and impressed the market with its second quarter results, announcing earnings per share of USD1.32, ahead of the consensus expectation of USD1.23. Pepsico shares are moving higher in the premarket.

Amid a heightened focus on the airline after it decided to cancel all flights to Tel-Aviv on Tuesday due to a rocket exploding near the airport, Delta Airlines has reported second quarter earnings per share of USD0.94, up from USD0.8 a year earlier.

The US followed Delta's decision with a short-term ban on all flights to Tel-Aviv's Ben Gurion airport, although that didn't stop Secretary of State John Kerry landing there earlier Wednesday to attempt to advance ceasefire talks as the death toll from the conflict nears 650. The longer a flight ban to Tel-Aviv lasts, the greater the pressure on the US to broker a solution, both from the perspective of the economic effect on Israel, and frustrated US-Israelis and influential American Jews. Former New York Mayor Michael Bloombeg issued a statement Wednesday saying, "the flight restrictions are a mistake that hand Hamas an undeserved victory and should be lifted immediately."

US MBS mortgage applications jumped 2.4% in the week ended July 18, after falling 3.6% in the previous week. The only other release of note in the data calendar Wednesday is the eurozone consumer confidence index at 1500 BST, which is expected to remain unchanged in July at negative 7.5.

Ahead of the US opening bell, UK stocks are continuing to trade modestly higher, with the FTSE 100 up 0.2% at 6,806.01, the FTSE 250 up 0.3% at 15,697.82, and the AIM All-share up 0.1% at 773.07.

GlaxoSmithKline has dropped to the bottom of the FTSE 100, down 2.9%, after reporting a drop in first-half pretax profit to GBP1.89 billion from GBP2.70 billion in the previous year. Group revenue was also down to GBP11.17 billion from GBP13.1 billion. Glaxo said that full-year core earnings per share is now expected to be broadly similar to 2013.

Bank of England Governor Mark Carney has been speaking at a business conference in Glasgow ahead of the opening of the Commonwealth Games there, and following the release of the the latest BoE meeting minutes earlier Wednesday. After beginning with a games pun about the UK economy being the current holder of "fastest growing advanced economy in the world title," Carney went on to put the quarterly inflation report, due next month, squarely in focus for central bank watchers.

The BoE chief reiterated his recent message that real wage growth is now the key indicator as to when rates will rise, and that currently there are conflicting messages in the labour market, namely that unemployment is rapidly falling, but wage growth is stagnant.

"A key judgement for the MPC is when and to what extent these developments will translate into real wage growth, and in turn that wage growth into price pressures," Carney said. "Next month's Inflation Report provides the next opportunity to update our thinking on these important questions."

Carney also reiterated that the main risk to the UK economic recovery is an overheating of the housing market and the prospect of UK households indebtedness, which he used as one of the explanations for future rate rises being gradual.


By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.